ththWILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.cri ...

NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Charles River Laboratories International, Inc. ("Charles River" or the "Company") (NYSE: CRL). In February 2023, the Company disclosed that it had received a subpoena from the U.S. Department of Justice relating to an ongoing investigation in conjunction with the U.S. Fish ...

Valued at a market cap of $10.8 billion, Charles River Laboratories International, Inc. (CRL) is a global contract research organization (CRO) headquartered in Wilmington, Massachusetts. It supports the drug discovery and development process for pharmaceutical, biotechnology, medical device, and government clients worldwide. It is expected to announce its fiscal Q4 earnings for 2025 soon. Before this event, analysts expect this healthcare company to report a profit of $2.33 per share, down 12.4% from $2. ...

Acquisitions - Charles River announced the strategic acquisition of K.F. (Cambodia) Ltd. for approximately $510 million, expected to complete in Q1 2026, to self-supply most annual NHP needs[4] - The company will also acquire the remaining 79% of PathoQuest for about €51.60 million (approximately $60 million), expected to contribute $15-20 million in revenue in 2026[4] Supply Chain and Technology Enhancement - The acquisition of K.F. will aid in vertical integration amid global NHP resource constraints, enhancing DSA business stability and cost control[5] - PathoQuest's NGS quality control technology will improve NAMs and bioproduct quality control, increasing the proportion of high-value services[5] DSA Demand Recovery - DSA net book-to-bill ratio reached 1.1x in Q4 2025, up from 0.8x in Q2-Q3 2025, indicating a recovery driven by small and medium biotech demand and growth in large pharma orders[6] - This recovery signals a gradual bottoming out of preclinical demand[6] 2026 Performance Outlook - The company is cautiously optimistic for 2026, expecting organic revenue growth to be at least flat, with DSA business resuming organic growth in H2 2026[6] - Forex is expected to contribute 100-150 basis points to revenue growth[6] Investment Recommendations - Long-term positive outlook on pharmaceutical growth, with a focus on domestic companies such as WuXi AppTec and Pharmaron[7] - Suggested companies to watch include WuXi AppTec, Pharmaron, JOINN Laboratories, and others[7] Risk Factors - Risks include a weaker-than-expected global biotech financing environment and challenges in NHP supply chain recovery[7] - Potential risks related to acquisition integration and project execution[7]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

PresentationHi, everybody. Welcome to the JPMorgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by Charles River Labs CEO, Jim Foster. Jim is going to give the corporate presentation, and then we'll jump right into Q&A afterwards. Jim, the floor is yours.James FosterChairman, President & CEO Thanks so much. Pleasure to be here, as always. Our safe harbor, Reg G and quiet period disclaimers. So we are a nonclinical CRO working with clients f ...

Charles River Laboratories (NYSE:CRL) FY Conference January 13, 2026 01:30 PM ET Company ParticipantsJames C. Foster - CEOConference Call ParticipantsCasey Woodring - AnalystNoneYeah.Casey WoodringHi, everybody. Welcome to the J.P. Morgan Healthcare Conference. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Pleased to be joined by Charles River Labs CEO, Jim Foster. Jim's going to give the corporate presentation, then we'll jump right into Q&A afterwards. Jim, the floor is yours.James ...

Financial Performance - The company's LTM 2025 revenue was approximately $40237 billion, with the DSA segment contributing 6001%[13,74] - The company expects to deliver approximately $295 million in cumulative, annualized cost savings by 2026[48] - The company's capital expenditures represented 51% of LTM revenue, compared to a peak of 82% in 2022[54] - Approximately $450 million in stock repurchases were made in 2024-2025[54] Market Position and Strategy - The company supported over 80% of FDA-approved novel drugs in the last five years (2021-2025)[11] - The company estimates the addressable market opportunity to be approximately $25 billion[11] - The company's revenue from the biopharma industry is approximately 70%[9] - The company plans to divest underperforming or non-core assets representing approximately 7% of 2025E revenue[52] Acquisitions and Outlook - The company plans to acquire K.F. (Cambodia) Ltd for approximately $510 million, expected to close in early Q1 2026[53] - The company plans to acquire the remaining 79% equity stake of PathoQuest SAS for approximately $60 million, expected to close by the end of Q1 2026[53] - PathoQuest is expected to generate $15-$20 million in 2026 annual revenue[53]

Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of t... ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates. ...